Connect insights across histology, biology, endpoints, and outcomes data for results that matter.
Clinical evidence and endpoints matter
The Oncotype DX GPS test has been developed and studied in over 9000 patients.1-12,14-23 The test provides crucial endpoints with actionable data to help address the needs of each patient.
Adverse Pathology: Predicts the risk of aggressive disease at the time of biopsy1,2
Metastasis and Prostate Cancer Death: Long-term endpoints predict future tumor behavior to ease patient concerns and offer reassurance3,14,15,23
Genomic testing is included in NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) and American Urological Association/American Society for Radiation Oncology (AUA/ASTRO) guidelines.
NCCN Guidelines® include the GPS test as a Category 2A molecular testing option for consideration in prostate cancer patients with low- and favorable intermediate-risk disease (life expectancy >10 years).13,24
Talking to your patients
It can be overwhelming for patients to remember all the information they are told during an office visit. During patient conversations, you can go over these points:
- Resources are available that may be helpful in discussing prostate cancer and genomic testing
- A genomic test measures the expression of genes within a sample of tumor tissue1
- The Oncotype DX GPS test is a genomic test, and the results can help determine how aggressive the patient’s cancer is1
Coverage and financial assistance
The GPS test is widely accessible, with minimal out-of-pocket costs for most patients.†
†The Oncotype DX GPS assay is performed on claims with the unique proprietary laboratory analysis (PLA) code, 0047U.
Is your patient eligible?
The Oncotype DX Genomic Prostate Score assay is for patients who have:
- Biopsy within 3 years
- Not started treatment
- Localized prostate cancer*
*Excludes NCCN very-high-risk prostate cancer. Patients with NCCN very-low-, low-, intermediate-, and high-risk disease are eligible.